us Thank joining you the you for result first our health are advance the workers public the facing a to And Thank I'll you start difficulties responders mission, TX lifetime. challenges and greatest thank service your our hardships despite all globe across commitment and all as for by unwavering recognizing to created Biosystems the sacrifice. to your we challenge pandemic. my for colleagues COVID-XX all you, Thank the ongoing of at of and by of Philip. the healthcare today.
in Two, impact make closing September by detailed progress the three financial our our milestone reductions. priorities. contract, provide will to by operations prioritizing in XXXX. then And million then cost our government the the pipeline I each of the utilization. and prioritizing based with accelerating we'll programs by John improving start I'll of under a first made today's advancing On awarded of some three, review will the One, by remarks, test prioritizing discuss and development open product performance questions U.S. quarter, and Sprague the significant our increased COVID-XX, our quarter answers. sales our the for $XX corporate call including call, results.
the to team of total million the announced, Biosystems we XX% generated quarter of of in compared period. $X.X year As an TX revenue prior first increase XXXX, the
We the clinicians around continue hospitals TXDx aid to and supply to the of TXResistance our our rapid TXCandida Panels in TXBacteria, instruments globe, causing pathogens. detection and substance to
our test, the to COVID-XX which development the molecular include TXSARS-CoV-X the committed priorities, fully XXXX now are of diagnostic We branded as Panel.
important to and have believe going the our steps We significantly one we provides during which than balance operating year taken more forward. reduce quarter, sheet of our strengthen to expenses cash
pandemic, financial the on related ongoing disruption operational for the XXXX. and and XX, uncertainty suspended we Given guidance to March
hospitals to As COVID-XX, treatment the new identification, of and resources technologies. management evaluations bandwidth undergone limited advance with extreme have changes patients currently on have to they their of focus
caring for critical access directors doctors sales frontline including also team. nonessential our personnel, Hospitals affairs are and patients. pharmacists, and include, for disease customers service and based limited on and to laboratory hospital Our medical have who access teams, care restricted the and infectious our
remain conditions we're engaged commercial these technology as possible. headwinds, using much While created to our have as with customers
essential can intensive population demonstrated Data frequent to care an in in cause that secondary orders, continuing are given has are susceptible units. their co-infections some our of our that to We're value larger and patient patients cases, of that time, the the COVID-XX most same platform orders, element or to and more sepsis. pleased infections proven customers. for the note our has At to place be customers
testing more geographies York at effectively. have and this heavily patients impacted Greece. rates of Italy, to help and City, understand seeing manage accounts been our like that by cases, connection, COVID-XX and Spain, New tests customers using are increased Our We're
In staggering. A XX globally. subsections million all States forms costs, deaths XXX,XXX year. in die $XX found United of States, from more is deaths deaths, healthcare cancer most people killing cost worldwide sepsis that the sepsis approximately five and year. severity combined. recent cause sepsis The and contributes study the are of in-hospital each in in billion then nearly represents to the common people than That's And United one hospital nearly each
technology need new to the when positive identify of as up sepsis. of only the are saving Saving cleared by our five increases delayed who TX risk hours, three For causing to to mortality FDA X%. At such hour products those, each blood, directly in suspected blood includes wait to to pathogens without treatment, culture. for Biosystems, time lives, means days a managing patients targeted from
Rapid pathogen enable and resistance. of antibiotics growth broad spectrum prevent targeted help combat antibiotic use can of reduce identification in antimicrobial quicker administration therapy, unnecessary and to
possible. the not This is based adjust current possible plan game as under further we’ve will or assumptions is predicting are business. we a duration, of Regarding our institutional COVID-XX running a our dynamic fluid business, and information, we impacts resurgences and on But set created new which is on information available. our changes situation,
identify could curve continue of Panel hopeful TXSARS-CoV-X infections. related We and to continues current our log tools prove to COVID-XX. believe COVID-XX rates measures will be effective. products detection distancing, to remain potentially infections development the of crucial secondary flatten And and social co-infections infection other that that in currently We to precautionary primary to the the
advancing the shift sales, operations, now we for corporate success to to and accelerating We'll our our gears three drive company, pipeline. long-term priorities discuss our established improving the
our priority, accelerating by start sales. our first Let's addressing
assumptions quarter all strategy. CEO, we During to challenged my related our first as commercial
utilization of in we've adoption of our commercial We to traction strategy to result, a instruments. on among rather right installed metrics the quarter. focus given driving number of placed instruments our TXDx are focus demonstrate As increasing the on shifted our of a believe and base these than tests the our instruments, historical
of on U.S. access gain are customers to we commercial affiliated group We targeting to organizations our where members contracts. market current hospitals also our prioritizing those purchasing accounts. more within new the stakeholders are hospitals and and efforts direct focusing have that We're
clinical XX% and incremental the TXCandida of Vizient our recommendation the quarter, During includes were innovative in market. medical on of sells organization benefits a awarded United XX% nation's on and purchasing Council, TXBacteria other that contract care the hospitals, centers market. the experts a country’s Inc, was products Vizient products. contract instrument more the the and ambulatory group than acute The largest multiyear of offer TXDx academic by to the Vizient Vizient, Panels, we States technology from Member all compared XX% and based first
contracts hospitals and Vizient, contract awarded increase who into a facilitate We activities. pricing prestigious validate with visibility with us in believe XXXX, like organizations, our sales and technology, entering September, our Premier, technology breakthrough
protocols, input directors, in expand us We and to transplant management created are understand intensive within such strategy hospital these commercial and further care, our and sepsis messaging oncology address clinicians to due as from of target focusing To products to complexity our this for in our target typically to address departments. providers essential used, is We the clinicians, it where are of relationships stakeholders refined lab with clinicians, the group the high-risk better U.S. departments, are units. which administrators. these multiple our we've hospital,
their body To liaisons with resonating cases of tests with hospital. the we objectives, by active that clinical U.S. into traction early made accounts and weighting, to science and key and utilization. orders sales our playing with role test our are within incentive-based compensation changes pleased medical integrating on evidence basis. protocols, sales on placing Our here, We're these a sepsis routine are realign plans heavily compensation to the a used the stakeholders see management in expanding team demonstrating
active of in Instruments and end the to we prior saw black, slight the sequential compared run per was At annual active installed the a quarter, the of first quarter. increase utilization test instrument, TXDx rate base the
our conditions. view convert to need, both encouraged by see fills contracts, strong This under under period delayed agreements, to despite platform while associated spite in that still were challenges that We was also that of market instruments unmet in an are progress with evaluation delivering reagent instruments to an offset rental COVID-XX. and been evaluation the current capital ongoing We're COVID-XX. are signals has hospitals these to that the due value
diagnostic some before, with strong however, disruption slowed, Interest the COVID-XX. from evaluating from did TXDx Internationally, We in Spain, utilization underway. COVID-XX in the mentioned that Instruments and in similar did market hardest already test as Europe areas hit experienced like Italy, Greece. I progress healthcare were customers with evaluations that infections,
inform TXResistance Panel, the which we our first for pleased commercial to TXResistance clinical that early approval I'm Europe. use. And Mark traction we're CE implemented routine hospital customer, in our now gaining you have into recent Panel the Following
distributors. And such be remain the of opportunities business the pursue to second by with international that partnering large during commercial strengthen we agreement Finally, our strategic continue XXXX. first optimistic may completed quarter to we
XX%. that I undergo In changes to Moving call scope the business, need of profile our know conjunction a of reduction. facilities reduction strategic our in resulting real we’ve And shifts, position space of as consolidate result a would to that based to on to in expense with the workforce observations, and operations. of current our plan resulting conditions, on the my a sustain financial strength. priority, affect headcount company's initial a our size significant restructured and and the second improving current we our last to estate market
expenses dive that costs across not deep We also examination eliminated did a support our conducted strategy. and all departments new of
reflect expenses cost will continue aim build the changes we upon to new these savings quarter throughout Second these and to year.
also forward. focus We on product revenues cost of improving the moving will
our and materials, supply and our operational shipping. of our packaging, As did ordering with we we products for conducted thorough chain, current manufacturing, a evaluation including expenses, raw processes
goods. the going be designed At product initiatives our gross to impact we have during initiatives of second XXXX, We on completed and reduce these numerous quarter our anticipate margins of the will will cost many implemented XXXX, a of beginning positive forward. of
our pipeline. to third advancing Looking our priority,
million platform. panel. working of scientific experts government biothreat to powered team awarded proprietary expand contract the instrument, by TX's continually are technology panel U.S. and create development by offering, Last $XX a our to a expanded the year, milestone-based company generation was product next Our
than It's bacterial We more developing species. of cover blood to potential panel detect we're greater blood replace susceptibility XXX than potentially borne most believe to cultures XX% results. revolutionize diagnostic and for the the could designed being has blood and potentially the identification infections all species space, and performed comprehensive
addition be Control a government In drugs pathogens is high-sensitivity, believe borne whole blood will Disease biothreat and biothreat resistant of the component antibiotic and identified the test of Centers we panel last for by first Prevention. multiple that genes. all detection The toxin the to contract the for blood
license to to and that determined launch the explored We against versatility most platform scientific further the COVID-XX the information from COVID-XX. Discovery information Meridian path the diagnostic we test Health. assist of technology with that from Hackensack we was the of develop possible means licensed we molecular test the our will is proprietary and viruses’ The detect Center efficient presence of certain and development Given expertise, for of proprietary the at Innovation efforts believe diagnostic to our SARS-CoV-X our material. genetic Hackensack accelerating
development making TXSARS-CoV-X is progress forward sample, launching TX come nasopharyngeal we have the we're designed about on excited We're quality expect Biosystems. to to which believe the the use we look to from a of that molecular will swab provide customers the and Panel, test diagnostic
as available to Panel Use of TXSARS-CoV-X this FDA to is anticipate formal guidelines time, customers Authorization plan as we customers we making available the to it Panel At the development quarter. Emergency pursue under this U.S. FDA completed, the the and EUA. end our make Once early TXSARS-CoV-X validated,
for continues evolve, pandemic. to market to as the The the industry COVID-XX responds test diagnostic potential
to in castrated we've acute and market, antibody tests succeed will COVID-XX seen identify other we molecular As multiple active to cases, tests, identify tests or with the diagnostic including diagnostic believe tests many infections.
clinics. believe performed pointed locations, COVID-XX parasites hospitals, tests and doctor in offices laboratories, also be will including weapons multiple like We and
rapid up patients faster ill and that TXBacteria the also which the our free intensive and develop enable incoming stay who targeted infections, of can results TXSARS-CoV-X early to under Given Panels. molecular in intensive fungal potential infections secondary target may our the reduce to length lead believe test susceptibility setting COVID-XX of therapy, Providing used to and identify and sepsis, lead to bacterial acute co-infections identification patients. benefit TXCandida to or care, of with in patients can for beds from can has critically we care this infections be unit,
results. call John? the our CFO, our Sprague turn to financial first on I'll John details provide Now quarter to over
